¹ØÓÚÂýÐԸβ¡»¼ÕßѪÇå²ãÕ³µ°°×¼°Í¸Ã÷ÖÊËáµÄ±ä»¯µÄÔÒò,¹ØÓÚÂýÐԸβ¡»¼ÕßѪÇå²ãÕ³µ°°×¼°Í¸Ã÷ÖÊËáµÄ±ä»¯µÄÏà¹ØÖªÊ¶¡£ ½â·Å¾ü454Ò½Ôº´«È¾¿Æ ½ËÕÊ¡ÄϾ©ÊÐ 210002
ÅËÑ©·É£¬ÄУ¬1958-02-05Éú£¬½ËÕÊ¡ÎÞÎýÊÐÈË£¬ºº×å.ҽѧ˶ʿ£¬´«È¾¿ÆÖ÷ÖÎҽʦ£¬Ö÷Òª´ÓÊ¸ε¨²¡µÄÁÙ´²¼°Ñо¿£¬·¢±íÂÛÎÄ10ƪ
ÏîÄ¿¸ºÔðÈË ÅËÑ©·É,210002 ½ËÕÊ¡ÄϾ©ÊÐÂí·½Ö32ºÅ,½ËÕÊ¡ÄϾ©ÊÐ,½â·Å¾ü454Ò½Ôº´«È¾¿Æ
Tel: 025-6649838-13ÊÕ¸ãÈÕÆÚ 1995-07-09 ½ÓÊÕÈÕÆÚ 1995-10-02
Alterations of serum laminin and hyaluronic acid in patients with chronic liver diseasesª¤ª¤
Xue-Fei Pan, Chang-Fa Zhang, Wei-Wei Qiu, Guo-Qiang Lu, Min-Wei Zhou,Jie Chang, Ying Ni, Sheng-Qing Li and Ting-Qin Han
Department of Infectious Diseases, Chinese PLA 454 Hospital, Nanjing 210002 Jiangsu Province, Chinaª¤
Abstractª¤
AIMS To study the clinical significance of serum laminin(LN) and hyaluronic acid(HA) in patients with chronic liver diseases.ª¤
METHODS The concentrations of serum LN and HA in patients with acute (n=10) or chronic hepatitis (n=39) and cirrhosis (n=27) were detected by using IRA. The relation between LN, HA and liver function and pathology was analysed.ª¤
RESULTS Serum LN in patients with chronic hepatitis(CH) and cirrhosis is much higher than those in patients with acute hepatitis and healthy people. Serum LN in patients with cirrhosis was 1.8 times as high as CH(P<0.01). If the levels of serum HA and LN were defined to 400 and 150¦Ìg/L respectively, serum HA and LN increase accounted for 85.2% in cirrhosis but 9.7% in CH. The difference is very obvious between two groups(P<0.01). Serum LN increased obviously in patients with early chronic hepatitis C. Liver FSC and fibrocytes were increased under electro-microscope.ª¤
CONCLUSIONS The concentrations of serum LN and HA are useful in the differential diagnosis of liver cirrhosis and fibrosis.ª¤
Subject headings laminin /blood hyaluronic acid/blood hepatitis, viral, human/blood liver cirrhosis/blood
Pan XF, Zhang CF, Qiu WW, Lu GQ, Zhou MW,Chang J, Ni Y, Li SQ,Han TQ.Alterations of serum laminin and hyaluronic acid in patients with chronic liver diseases.Xin Xiaohuabingxue Zazhi,1996£»4(7)£º373-374
ÕªÒª
Ä¿µÄ Ñо¿ÑªÇå²ãÕ³µ°°×(LN)ºÍ͸Ã÷ÖÊËá(HA)¶ÔÂýÐԸβ¡µÄÕï¶ÏÒâÒå.
·½·¨ ¼ì²â¼±ÂýÐÔ¸ÎÑ×¼°¸ÎÓ²±ä»¼ÕßѪÇåLNºÍHAŨ¶È£¬Óë¸Î¹¦Äܼ°Ê³¹Ü¾²ÂöÇúÕų̶Ⱥ͸ÎÔಡÀí½øÐбȽÏ.
½á¹û ÂýÐÔ¸ÎÑ×ѪÇåLNÃ÷ÏÔ¸ßÓÚ½¡¿µÕߺͼ±ÐÔ¸ÎÑ×£¬¸ÎÓ²±ä»¼ÕßѪÇåLNÉý¸ß·ù¶È½Ï´ó£¬ÊÇÂýÐÔ¸ÎÑ×(CH)»¼ÕßµÄ1.8±¶(P<0.01). HAÒÔ400¦Ìg/LΪ½ç£¬LNÒÔ150¦Ìg/LΪ½ç£¬¸ÎÓ²±äͬʱÉý¸ßÕßÕ¼85.2%. CHÔòΪ9.7%£¬Á½×é±È½Ï²îÒì·Ç³£Ã÷ÏÔ(P<0.01). ÂýÐÔ±ûÐ͸ÎÑ×»¼ÕßÔçÆÚѪÇåLN¾ÍÏÔÖøÉý¸ß£¬µç¾µ¹Û²ì·¢ÏÖ±ûÐ͸ÎÑ×»¼ÕßÖü֬ϸ°û¼°³ÉÏËάϸ°ûÔö¶à£¬´ËÖÖ²¡ÀíÏÖÏó½ÏCH»¼ÕßÃ÷ÏÔ.
½áÂÛ ÁªºÏ¼ì²âѪÇåLNºÍHA¶ÔÇø·Ö¸ÎÏËά»¯Óë¸ÎÓ²±äÓÐÒâÒå.
Ö÷Ìâ´Ê ͸Ã÷ÖÊËá/ѪҺ;²ãÕ³µ°°×/ѪҺ;¸ÎÑ×£¬²¡¶¾ÐÔ£¬ÈË/ѪҺ;¸ÎÓ²»¯/ѪҺ
ÅËÑ©·É,Õų¤·¨,Çñεε,ÂÀ¹úÇ¿,ÖÜÃ÷ΰ,³£½à,ÄßÓ±,ÀîÊ¥Çà,º«Í£ÇÙ.ÂýÐԸβ¡»¼ÕßѪÇå²ãÕ³µ°°×¼°Í¸Ã÷ÖÊËáµÄ±ä»¯.
ÐÂÏû»¯²¡Ñ§ÔÓÖ¾£¬1996£»4(7)£º373-374
½ü10ÄêÀ´¸ÎÔàÏËά»¯±êÖ¾ÎïµÄÑо¿½øÕ¹½Ï¿ì£¬Îª½øÒ»²½Ì½ÌÖ²ãÕ³µ°°×(laminin, LN)ºÍ͸Ã÷ÖÊËá(HA)·Ç½ºÔµ°°×³É·ÖµÄÕï¶ÏÒâÒ壬ÎÒÃÇÁªºÏ¼ì²â¼±ÂýÐÔ¸ÎÑ׺͸ÎÓ²±ä»¼ÕßµÄѪÇåLNºÍHA£¬±¨¸æÈçÏÂ.ª¤ª¤
1 ¶ÔÏóºÍ·½·¨ª¤
1.1 ¶ÔÏó ¸ù¾Ý1990ÄêµÚÁù´ÎÈ«¹ú¸ÎÑ×»áÒéÕï¶Ï±ê×¼£¬¼±ÐÔ»ÆðãÐÔ¼×Ð͸ÎÑ×10Àý£¬ÄÐ8Àý£¬Å®2Àý£¬Æ½¾ùÄêÁä27.3¡À11.4ËꣻÂýÐÔ¸ÎÑ×(CH)39Àý£¬ÆäÖÐÒÒÐ͸ÎÑ×26Àý£¬ÄÐ21Àý£¬Å®5Àý£¬Æ½¾ùÄêÁä29.6¡À13.4Ëꣻ²¡³Ì4.16¡À1.24Äꣻ±ûÐ͸ÎÑ×13Àý£¬ÄÐ10Àý£¬Å®3Àý£¬Æ½¾ùÄêÁä37.2¡À14.9Ë꣬²¡³Ì2.34¡À0.67Äꣻ¸ÎÑ׺ó¸ÎÓ²±ä27Àý£¬ÆäÖÐʧ´ú³¥ÆÚ25Àý£¬´ú³¥ÆÚ2Àý£¬ÄÐ23Àý£¬Å®4Àý£¬Æ½¾ùÄêÁä45.5¡À14.8Ë꣬ƽ¾ù²¡³Ì
4.56¡À3.24Äê.ª¤
1.2 ·½·¨ »¼Õ߿ո¹³éѪ5mlÀ䲨±¸¼ì£¬²ãÕ³µ°°×ºÍ͸Ã÷ÖÊËáÊÔ¼Á¾ùΪÉϺ£º£ÑÐҽѧÉúÎïÖÐÐÄÌṩ£¬Ó÷ÅÃâ·¨²â¶¨.ͬʱ²é¸Î¹¦ÄÜ¡¢ÑªÇå°×µ°°×¡¢×ܵ¨ºìËØ£¬¸÷ÖÖ²¡¶¾±êÖ¾Î¸ÎÓ²±äÕßÐбµ²Í͸ÊÓ£¬½«Ê³¹Ü¾²ÂöÇúÕÅ£¬·ÖΪÇá¡¢ÖС¢ÖØ.²¿·Ö»¼ÕßÐиδ©´Ì£¬±ê±¾Í¬Ê±Óù⾵ºÍÓÃDXA4-10Ð͵羵¼ì²é.ª¤ª¤
2 ½á¹ûª¤
2.1 ¸÷Ð͸β¡ÑªÇåLNºÍHAˮƽ ±í1.ª¤
±í1 ¸÷Ð͸β¡ÑªÇåLNºÍHAˮƽ (x-¡Às, ¦Ìg/L)ª¤
aP<0.05£¬bP<0.01.ª¤ª¤
2.2 ѪÇåLNÓë¸Î¹¦ÄܵÄÏà¹ØÐÔ ÂýÐԸβ¡ÑªÇåLNÓëѪÇåALT¡¢×ܵ¨ºìËØ¡¢ÑªÇåÇòµ°°×³ÉÕýÏà¹Ø(P<0.05)£¬ÓëѪÇå°×µ°°×¡¢µ¨¼î֬ø³É¸ºÏà¹Ø(P<0.01)£¬Óëʳ¹Ü¾²ÂöÇúÕų̶ȳÉÕýÏà¹Ø(P<0.05).ª¤
2.3 ѪÇåLNºÍHAµÄ¼ø±ðÕï¶ÏÒâÒå HAºÍLN·Ö±ðÒÔ400ºÍ150¦Ìg/LΪ½ç£¬¸ÎÓ²±ä¸ßÓÚ´ËÖµÕß·Ö±ðÕ¼85.2%ºÍ92.5%£¬Í¬Ê±Éý¸ßÕßÕ¼85.2%.CHÔò·Ö±ðÕ¼9.7%£¬16.1%ºÍ9.7%£¬ÁÙ½çÖµÁ½×éLN£¬HA¾Í³¼ÆÑ§´¦Àí²îÒìÊ®·ÖÏÔÖø(P<0.01£¬±í2).ª¤
±í2 Á½×éLNºÍHAÁÙ½çÖµ·Ö²¼ (µ¥Î»¦Ìg/L)
2.4 ²¡Àí¹Û²ì ÂýÐÔ±ûÐ͸ÎÑ׸Î×éÖ¯£¬¾ù¿É¼ûµ½Öü֬ϸ°û£¬ÇÒÊýÁ¿½Ï¶à£¬»ã¹ÜÇøÍ¬Ê±¿É¼ûµ½´óÁ¿ÏËάĸϸ°û£¬ÂýÐÔÒÒÐ͸ÎÑ×δ¼ûµ½´ËÏÖÏó.¸ÎÔà»ã¹ÜÇøµ¥ºËϸ°ûÁܰÍϸ°ûºÍ·Ê´óϸ°û½þÈó¼°¾ÞÊÉϸ°û»îÔ¾£¬Æä³Ì¶È±ÈÂýÐÔÒÒÐ͸ÎÑ׵ĸıä¸üΪÃ÷ÏÔ.ѪÇåLNÓ벡ÀíÖü֬ϸ°û¡¢ÏËάĸϸ°ûÊý³ÉÕýÏà¹Ø(P<0.01).ª¤ª¤
3 ÌÖÂÛª¥
Õý³£¸ÎÔàϸ°ûÍâ¼äÖÊ(extracellular matrix, ECM)Ö÷ÒªÓнºÔ¡¢Õ³Á¬µ°°×¡¢LNºÍµ°°×¶àÌÇ.¸ÎÏËά»¯Ê±Ï¸°ûÍâ¼äÖʳɷÖÒì³£Ôö¶à£¬³Á»ýÓÚ¸ÎÔà×éÖ¯ÖУ¬³ý½ºÔÏËάÍ⣬·Ç½ºÔÐÔ¼äÖʳɷÖÒ²´óÁ¿Ôö¼Ó[1£¬2].ÎÒÃǹ۲쵽ÂýÐÔ¸ÎÑ×LNÃ÷ÏÔ¸ßÓÚ½¡¿µÕߺͼ±ÐÔ¸ÎÑ×£¬Ô¼Îª1.70Óë1.35±¶.¸ÎÓ²±ä»¼ÕßѪÇåLNÉý¸ß·ù¶È½Ï´ó£¬ÓëCHÏà±È²îÒìÒà·Ç³£Ã÷ÏÔ£¬ÊÇCH»¼ÕßµÄ1.8±¶.HAÒÔ400¦Ìg/LΪ½ç£¬LNÒÔ150¦Ìg/LΪ½ç£¬¸ÎÓ²±äͬʱÉý¸ßÕßÕ¼85.2%.CHÔòÕ¼9.7%.Á½×é±È½Ï²îÒì·Ç³£Ã÷ÏÔ.1ÀýÖØÖ¢¸ÎÑ×ѪÇåHAŨ¶ÈºÜ¸ß£¬µ«ÑªÇåLNŨ¶È²¢²»¸ß£»Ïà·´1Àý¸Î²¡»¼Õß¼¸ÎÞÖ¢×´£¬²éѪÇåLNºÍHA´ïµ½Õï¶Ï±ê×¼£¬×îºóÈ·ÕïΪ¸ÎÓ²±ä.GressnerµÈ[3]·¢ÏÖ£¬LNˮƽÓëÞ²ÂöѹÁ¦Óйأ¬¶þÕß³ÊÕýÏà¹Ø.Íõ½Ü¾üµÈ[4]¹Û²ìµ½ÑªÇåLNˮƽ¸ÎÓ²±ä¡¢Âý»î¸Î¸ßÓÚÕý³££¬ÑªÇåLNˮƽÓë¸ÎÏËά»¯¡¢¸ÎÄÚÑ×ϸ°û½þÈ󡢸Îϸ°û»µËÀ±äÐÔ¼°¸Îñ¼ÄÚ»ùµ×ĤÐγɳÊÕýÏà¹Ø.¸ß·åµÈ[4]·¢ÏÖѪÇåLNº¬Á¿ÔÚ´óÊó¸ÎÔàÊÜËðºóÔçÆÚ¼´¿ªÊ¼Éý¸ß£¬¸ÎÔà×é֯ѧ¸Ä±ä¼°¸Î¹¦Äܱ仯ÏàÆ½ÐÐ.¸ÎÔȽ¬LNº¬Á¿ÔÚ¸ÎÓ²±äÍíÆÚ²ÅÉý¸ß£¬ÃâÒß×黯ҲÏÔʾLNÔÚ¸ÎÓ²±äÍíÆÚ³Á׿ÓÉî.¸ÎÓ²±äѪÇåHAŨ¶ÈÉý¸ß£¬ÑªÇåHAº¬Á¿Óë°ëÈéÌÇÄÍÁ¿ÊÔÑ顢ѪÇå°×µ°°×¡¢µ¨ºìËØ¡¢AST¼°ÄýѪøԪʱ¼äµÈ¾ùÓÐÃÜÇйØÏµ.ÁªºÏ¼ì²âѪÇåLNºÍHA´ËÁ½Ïîϸ°ûÍâ·Ç½ºÔ¼äÖʳɷݶÔÇø·Ö¸ÎÏËά»¯Óë¸ÎÓ²±äÓаïÖú[6].ª¥
ÎÒÃÇ»¹¹Û²ìµ½ÊäѪºó±ûÐ͸ÎÑ×»¼ÕßÔçÆÚѪÇåLN¾Í¿ªÊ¼Éý¸ß£¬ÒòÕâЩ»¼Õß¾ùÓÐÊäѪʷ£¬ÇÒÓÐÃ÷È·µÄÆð²¡Ê±¼ä£¬²¡³ÌÓëÂýÐÔÒÒÐ͸ÎÑ××éÏà±È£¬Ç°ÕßÃ÷ÏÔµÍÓÚºóÕߣ¬µ«ÑªÇåLN¾ùÃ÷ÏÔÉý¸ß.±ûÐ͸ÎÑ×»¼Õ߸ÎÔà×éÖ¯Öü֬ϸ°û¼°³ÉÏËάϸ°ûÔö¶à£¬´ËÖÖ²¡ÀíÏÖÏó½ÏCH»¼ÕßÃ÷ÏÔ£¬±íÃ÷±ûÐ͸ÎÑ×ÏËά»¯Æð²½¿ì.ÈôÖü֬ϸ°û±»¼¤»î£¬ÔòÄܺϳɢñ£¬¢óÐͽºÔ£¬ÒÔ¼°·Ç½ºÔµ°°×£¬´Ó¶øµ¼Ö¸ÎÓ²±ä.FSCÊǸÎÔà·ÇʵÖÊϸ°ûÖ®Ò»£¬²¢·¢ÏÖÖü֬ϸ°ûÓë³ÉÏËάϸ°ûÏàËÆ»òÈÏΪFSCÊǼ¡³ÉÏËάϸ°ûµÄǰÌå.Òò´Ë¶¯Ì¬¹Û²ìѪÇåLN£¬¶ÔÕÆÎÕ±ûÐ͸ÎÑ×ÏËά»¯µÄ³Ì¶ÈºÍ·¢Õ¹Ç÷ÊÆ¾ßÓÐÖØÒªµÄÁÙ´²ÒâÒå.ª¤ª¤
4 ²Î¿¼ÎÄÏ×
1 Fridman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis, 1990;10(1):20-29ª¤
2 ɽÄÚÕæÒ⣬ÖÐÔÕýÐÛ£¬»§Ìï¸ÕÌ«ÀÉ£¬µÈ.¸Î¼²»¼¤Ë¤©¤±¤ðϸ°ûÍâ¥Þ¥È¥ê¥Ä¥¯¥½¥¹³É·Ö²â¶¨¤ÎÁÙ´²µÄÒâÒå.ÄÚ¿Æ£¬1993£»71(2)£º236-239ª¤
3 Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: Role of fat-storing cells in fibrogenesis.
Semin Liver Dis, 1990;10(1):30-46ª¤
4 Íõ½Ü¾ü£¬¿×ÏÜÌΣ¬Àîʯ£¬µÈ.ѪÇå²ãÕ³µ°°×±ä»¯·´Ó³ÂýÐԸβ¡µÄ²¡Àí¸Ä±ä.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬1994;10(3):136-139ª¤
5 ¸ß·å£¬¿×ÏÜÌΣ¬Ð»Ó³»ª£¬µÈ.²ãÕ³µ°°×Óë¸ÎÓ²±äµÄ¶¯ÎïʵÑéÑо¿.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬1995£»11(1)£º34-36ª¤
6 Àî´«µÀ.¸ÎÏËά»¯ÑªÇå±êÖ¾ÎïµÄнøÕ¹.¹úÍâҽѧÁÙ´²ÉúÎﻯѧ¼ìÑé·Ö²á£¬1994£»15(1)£º3-53
ÅËÑ©·É£¬ÄУ¬1958-02-05Éú£¬½ËÕÊ¡ÎÞÎýÊÐÈË£¬ºº×å.ҽѧ˶ʿ£¬´«È¾¿ÆÖ÷ÖÎҽʦ£¬Ö÷Òª´ÓÊ¸ε¨²¡µÄÁÙ´²¼°Ñо¿£¬·¢±íÂÛÎÄ10ƪ
ÏîÄ¿¸ºÔðÈË ÅËÑ©·É,210002 ½ËÕÊ¡ÄϾ©ÊÐÂí·½Ö32ºÅ,½ËÕÊ¡ÄϾ©ÊÐ,½â·Å¾ü454Ò½Ôº´«È¾¿Æ
Tel: 025-6649838-13ÊÕ¸ãÈÕÆÚ 1995-07-09 ½ÓÊÕÈÕÆÚ 1995-10-02
Alterations of serum laminin and hyaluronic acid in patients with chronic liver diseasesª¤ª¤
Xue-Fei Pan, Chang-Fa Zhang, Wei-Wei Qiu, Guo-Qiang Lu, Min-Wei Zhou,Jie Chang, Ying Ni, Sheng-Qing Li and Ting-Qin Han
Department of Infectious Diseases, Chinese PLA 454 Hospital, Nanjing 210002 Jiangsu Province, Chinaª¤
Abstractª¤
AIMS To study the clinical significance of serum laminin(LN) and hyaluronic acid(HA) in patients with chronic liver diseases.ª¤
METHODS The concentrations of serum LN and HA in patients with acute (n=10) or chronic hepatitis (n=39) and cirrhosis (n=27) were detected by using IRA. The relation between LN, HA and liver function and pathology was analysed.ª¤
RESULTS Serum LN in patients with chronic hepatitis(CH) and cirrhosis is much higher than those in patients with acute hepatitis and healthy people. Serum LN in patients with cirrhosis was 1.8 times as high as CH(P<0.01). If the levels of serum HA and LN were defined to 400 and 150¦Ìg/L respectively, serum HA and LN increase accounted for 85.2% in cirrhosis but 9.7% in CH. The difference is very obvious between two groups(P<0.01). Serum LN increased obviously in patients with early chronic hepatitis C. Liver FSC and fibrocytes were increased under electro-microscope.ª¤
CONCLUSIONS The concentrations of serum LN and HA are useful in the differential diagnosis of liver cirrhosis and fibrosis.ª¤
Subject headings laminin /blood hyaluronic acid/blood hepatitis, viral, human/blood liver cirrhosis/blood
Pan XF, Zhang CF, Qiu WW, Lu GQ, Zhou MW,Chang J, Ni Y, Li SQ,Han TQ.Alterations of serum laminin and hyaluronic acid in patients with chronic liver diseases.Xin Xiaohuabingxue Zazhi,1996£»4(7)£º373-374
ÕªÒª
Ä¿µÄ Ñо¿ÑªÇå²ãÕ³µ°°×(LN)ºÍ͸Ã÷ÖÊËá(HA)¶ÔÂýÐԸβ¡µÄÕï¶ÏÒâÒå.
·½·¨ ¼ì²â¼±ÂýÐÔ¸ÎÑ×¼°¸ÎÓ²±ä»¼ÕßѪÇåLNºÍHAŨ¶È£¬Óë¸Î¹¦Äܼ°Ê³¹Ü¾²ÂöÇúÕų̶Ⱥ͸ÎÔಡÀí½øÐбȽÏ.
½á¹û ÂýÐÔ¸ÎÑ×ѪÇåLNÃ÷ÏÔ¸ßÓÚ½¡¿µÕߺͼ±ÐÔ¸ÎÑ×£¬¸ÎÓ²±ä»¼ÕßѪÇåLNÉý¸ß·ù¶È½Ï´ó£¬ÊÇÂýÐÔ¸ÎÑ×(CH)»¼ÕßµÄ1.8±¶(P<0.01). HAÒÔ400¦Ìg/LΪ½ç£¬LNÒÔ150¦Ìg/LΪ½ç£¬¸ÎÓ²±äͬʱÉý¸ßÕßÕ¼85.2%. CHÔòΪ9.7%£¬Á½×é±È½Ï²îÒì·Ç³£Ã÷ÏÔ(P<0.01). ÂýÐÔ±ûÐ͸ÎÑ×»¼ÕßÔçÆÚѪÇåLN¾ÍÏÔÖøÉý¸ß£¬µç¾µ¹Û²ì·¢ÏÖ±ûÐ͸ÎÑ×»¼ÕßÖü֬ϸ°û¼°³ÉÏËάϸ°ûÔö¶à£¬´ËÖÖ²¡ÀíÏÖÏó½ÏCH»¼ÕßÃ÷ÏÔ.
½áÂÛ ÁªºÏ¼ì²âѪÇåLNºÍHA¶ÔÇø·Ö¸ÎÏËά»¯Óë¸ÎÓ²±äÓÐÒâÒå.
Ö÷Ìâ´Ê ͸Ã÷ÖÊËá/ѪҺ;²ãÕ³µ°°×/ѪҺ;¸ÎÑ×£¬²¡¶¾ÐÔ£¬ÈË/ѪҺ;¸ÎÓ²»¯/ѪҺ
ÅËÑ©·É,Õų¤·¨,Çñεε,ÂÀ¹úÇ¿,ÖÜÃ÷ΰ,³£½à,ÄßÓ±,ÀîÊ¥Çà,º«Í£ÇÙ.ÂýÐԸβ¡»¼ÕßѪÇå²ãÕ³µ°°×¼°Í¸Ã÷ÖÊËáµÄ±ä»¯.
ÐÂÏû»¯²¡Ñ§ÔÓÖ¾£¬1996£»4(7)£º373-374
½ü10ÄêÀ´¸ÎÔàÏËά»¯±êÖ¾ÎïµÄÑо¿½øÕ¹½Ï¿ì£¬Îª½øÒ»²½Ì½ÌÖ²ãÕ³µ°°×(laminin, LN)ºÍ͸Ã÷ÖÊËá(HA)·Ç½ºÔµ°°×³É·ÖµÄÕï¶ÏÒâÒ壬ÎÒÃÇÁªºÏ¼ì²â¼±ÂýÐÔ¸ÎÑ׺͸ÎÓ²±ä»¼ÕßµÄѪÇåLNºÍHA£¬±¨¸æÈçÏÂ.ª¤ª¤
1 ¶ÔÏóºÍ·½·¨ª¤
1.1 ¶ÔÏó ¸ù¾Ý1990ÄêµÚÁù´ÎÈ«¹ú¸ÎÑ×»áÒéÕï¶Ï±ê×¼£¬¼±ÐÔ»ÆðãÐÔ¼×Ð͸ÎÑ×10Àý£¬ÄÐ8Àý£¬Å®2Àý£¬Æ½¾ùÄêÁä27.3¡À11.4ËꣻÂýÐÔ¸ÎÑ×(CH)39Àý£¬ÆäÖÐÒÒÐ͸ÎÑ×26Àý£¬ÄÐ21Àý£¬Å®5Àý£¬Æ½¾ùÄêÁä29.6¡À13.4Ëꣻ²¡³Ì4.16¡À1.24Äꣻ±ûÐ͸ÎÑ×13Àý£¬ÄÐ10Àý£¬Å®3Àý£¬Æ½¾ùÄêÁä37.2¡À14.9Ë꣬²¡³Ì2.34¡À0.67Äꣻ¸ÎÑ׺ó¸ÎÓ²±ä27Àý£¬ÆäÖÐʧ´ú³¥ÆÚ25Àý£¬´ú³¥ÆÚ2Àý£¬ÄÐ23Àý£¬Å®4Àý£¬Æ½¾ùÄêÁä45.5¡À14.8Ë꣬ƽ¾ù²¡³Ì
4.56¡À3.24Äê.ª¤
1.2 ·½·¨ »¼Õ߿ո¹³éѪ5mlÀ䲨±¸¼ì£¬²ãÕ³µ°°×ºÍ͸Ã÷ÖÊËáÊÔ¼Á¾ùΪÉϺ£º£ÑÐҽѧÉúÎïÖÐÐÄÌṩ£¬Ó÷ÅÃâ·¨²â¶¨.ͬʱ²é¸Î¹¦ÄÜ¡¢ÑªÇå°×µ°°×¡¢×ܵ¨ºìËØ£¬¸÷ÖÖ²¡¶¾±êÖ¾Î¸ÎÓ²±äÕßÐбµ²Í͸ÊÓ£¬½«Ê³¹Ü¾²ÂöÇúÕÅ£¬·ÖΪÇá¡¢ÖС¢ÖØ.²¿·Ö»¼ÕßÐиδ©´Ì£¬±ê±¾Í¬Ê±Óù⾵ºÍÓÃDXA4-10Ð͵羵¼ì²é.ª¤ª¤
2 ½á¹ûª¤
2.1 ¸÷Ð͸β¡ÑªÇåLNºÍHAˮƽ ±í1.ª¤
±í1 ¸÷Ð͸β¡ÑªÇåLNºÍHAˮƽ (x-¡Às, ¦Ìg/L)ª¤
| ·Ö ×é | n | LN | HA |
| ½¡¿µ×é | 18 | 97.67¡À23.56 | 53.22¡À36.73 |
| ¼±¸Î×é | 10 | 122.5¡À17.45a | 83.24¡À33.15a |
| Âý¸Î×é | 39 | 166.35¡À40.53b | 289.36¡À187.48b |
| ¸ÎÓ²±ä | 27 | 299.65¡À34.58b | 978.66¡À456.23b |
aP<0.05£¬bP<0.01.ª¤ª¤
2.2 ѪÇåLNÓë¸Î¹¦ÄܵÄÏà¹ØÐÔ ÂýÐԸβ¡ÑªÇåLNÓëѪÇåALT¡¢×ܵ¨ºìËØ¡¢ÑªÇåÇòµ°°×³ÉÕýÏà¹Ø(P<0.05)£¬ÓëѪÇå°×µ°°×¡¢µ¨¼î֬ø³É¸ºÏà¹Ø(P<0.01)£¬Óëʳ¹Ü¾²ÂöÇúÕų̶ȳÉÕýÏà¹Ø(P<0.05).ª¤
2.3 ѪÇåLNºÍHAµÄ¼ø±ðÕï¶ÏÒâÒå HAºÍLN·Ö±ðÒÔ400ºÍ150¦Ìg/LΪ½ç£¬¸ÎÓ²±ä¸ßÓÚ´ËÖµÕß·Ö±ðÕ¼85.2%ºÍ92.5%£¬Í¬Ê±Éý¸ßÕßÕ¼85.2%.CHÔò·Ö±ðÕ¼9.7%£¬16.1%ºÍ9.7%£¬ÁÙ½çÖµÁ½×éLN£¬HA¾Í³¼ÆÑ§´¦Àí²îÒìÊ®·ÖÏÔÖø(P<0.01£¬±í2).ª¤
±í2 Á½×éLNºÍHAÁÙ½çÖµ·Ö²¼ (µ¥Î»¦Ìg/L)
| ·Ö ×é | n | LN | HA | ||
| <150(%) | ¡Ý150(%) | <400(%) | ¡Ý400(%) | ||
| Âý¸Î×é | 31 | 26(83.9) | 5(16.1) | 27(90.3) | 4(9.7) |
| ¸ÎÓ²±ä | 27 | 2(7.4) | 25(92.6) | 4(4.8) | 23(85.2) |
2.4 ²¡Àí¹Û²ì ÂýÐÔ±ûÐ͸ÎÑ׸Î×éÖ¯£¬¾ù¿É¼ûµ½Öü֬ϸ°û£¬ÇÒÊýÁ¿½Ï¶à£¬»ã¹ÜÇøÍ¬Ê±¿É¼ûµ½´óÁ¿ÏËάĸϸ°û£¬ÂýÐÔÒÒÐ͸ÎÑ×δ¼ûµ½´ËÏÖÏó.¸ÎÔà»ã¹ÜÇøµ¥ºËϸ°ûÁܰÍϸ°ûºÍ·Ê´óϸ°û½þÈó¼°¾ÞÊÉϸ°û»îÔ¾£¬Æä³Ì¶È±ÈÂýÐÔÒÒÐ͸ÎÑ׵ĸıä¸üΪÃ÷ÏÔ.ѪÇåLNÓ벡ÀíÖü֬ϸ°û¡¢ÏËάĸϸ°ûÊý³ÉÕýÏà¹Ø(P<0.01).ª¤ª¤
3 ÌÖÂÛª¥
Õý³£¸ÎÔàϸ°ûÍâ¼äÖÊ(extracellular matrix, ECM)Ö÷ÒªÓнºÔ¡¢Õ³Á¬µ°°×¡¢LNºÍµ°°×¶àÌÇ.¸ÎÏËά»¯Ê±Ï¸°ûÍâ¼äÖʳɷÖÒì³£Ôö¶à£¬³Á»ýÓÚ¸ÎÔà×éÖ¯ÖУ¬³ý½ºÔÏËάÍ⣬·Ç½ºÔÐÔ¼äÖʳɷÖÒ²´óÁ¿Ôö¼Ó[1£¬2].ÎÒÃǹ۲쵽ÂýÐÔ¸ÎÑ×LNÃ÷ÏÔ¸ßÓÚ½¡¿µÕߺͼ±ÐÔ¸ÎÑ×£¬Ô¼Îª1.70Óë1.35±¶.¸ÎÓ²±ä»¼ÕßѪÇåLNÉý¸ß·ù¶È½Ï´ó£¬ÓëCHÏà±È²îÒìÒà·Ç³£Ã÷ÏÔ£¬ÊÇCH»¼ÕßµÄ1.8±¶.HAÒÔ400¦Ìg/LΪ½ç£¬LNÒÔ150¦Ìg/LΪ½ç£¬¸ÎÓ²±äͬʱÉý¸ßÕßÕ¼85.2%.CHÔòÕ¼9.7%.Á½×é±È½Ï²îÒì·Ç³£Ã÷ÏÔ.1ÀýÖØÖ¢¸ÎÑ×ѪÇåHAŨ¶ÈºÜ¸ß£¬µ«ÑªÇåLNŨ¶È²¢²»¸ß£»Ïà·´1Àý¸Î²¡»¼Õß¼¸ÎÞÖ¢×´£¬²éѪÇåLNºÍHA´ïµ½Õï¶Ï±ê×¼£¬×îºóÈ·ÕïΪ¸ÎÓ²±ä.GressnerµÈ[3]·¢ÏÖ£¬LNˮƽÓëÞ²ÂöѹÁ¦Óйأ¬¶þÕß³ÊÕýÏà¹Ø.Íõ½Ü¾üµÈ[4]¹Û²ìµ½ÑªÇåLNˮƽ¸ÎÓ²±ä¡¢Âý»î¸Î¸ßÓÚÕý³££¬ÑªÇåLNˮƽÓë¸ÎÏËά»¯¡¢¸ÎÄÚÑ×ϸ°û½þÈ󡢸Îϸ°û»µËÀ±äÐÔ¼°¸Îñ¼ÄÚ»ùµ×ĤÐγɳÊÕýÏà¹Ø.¸ß·åµÈ[4]·¢ÏÖѪÇåLNº¬Á¿ÔÚ´óÊó¸ÎÔàÊÜËðºóÔçÆÚ¼´¿ªÊ¼Éý¸ß£¬¸ÎÔà×é֯ѧ¸Ä±ä¼°¸Î¹¦Äܱ仯ÏàÆ½ÐÐ.¸ÎÔȽ¬LNº¬Á¿ÔÚ¸ÎÓ²±äÍíÆÚ²ÅÉý¸ß£¬ÃâÒß×黯ҲÏÔʾLNÔÚ¸ÎÓ²±äÍíÆÚ³Á׿ÓÉî.¸ÎÓ²±äѪÇåHAŨ¶ÈÉý¸ß£¬ÑªÇåHAº¬Á¿Óë°ëÈéÌÇÄÍÁ¿ÊÔÑ顢ѪÇå°×µ°°×¡¢µ¨ºìËØ¡¢AST¼°ÄýѪøԪʱ¼äµÈ¾ùÓÐÃÜÇйØÏµ.ÁªºÏ¼ì²âѪÇåLNºÍHA´ËÁ½Ïîϸ°ûÍâ·Ç½ºÔ¼äÖʳɷݶÔÇø·Ö¸ÎÏËά»¯Óë¸ÎÓ²±äÓаïÖú[6].ª¥
ÎÒÃÇ»¹¹Û²ìµ½ÊäѪºó±ûÐ͸ÎÑ×»¼ÕßÔçÆÚѪÇåLN¾Í¿ªÊ¼Éý¸ß£¬ÒòÕâЩ»¼Õß¾ùÓÐÊäѪʷ£¬ÇÒÓÐÃ÷È·µÄÆð²¡Ê±¼ä£¬²¡³ÌÓëÂýÐÔÒÒÐ͸ÎÑ××éÏà±È£¬Ç°ÕßÃ÷ÏÔµÍÓÚºóÕߣ¬µ«ÑªÇåLN¾ùÃ÷ÏÔÉý¸ß.±ûÐ͸ÎÑ×»¼Õ߸ÎÔà×éÖ¯Öü֬ϸ°û¼°³ÉÏËάϸ°ûÔö¶à£¬´ËÖÖ²¡ÀíÏÖÏó½ÏCH»¼ÕßÃ÷ÏÔ£¬±íÃ÷±ûÐ͸ÎÑ×ÏËά»¯Æð²½¿ì.ÈôÖü֬ϸ°û±»¼¤»î£¬ÔòÄܺϳɢñ£¬¢óÐͽºÔ£¬ÒÔ¼°·Ç½ºÔµ°°×£¬´Ó¶øµ¼Ö¸ÎÓ²±ä.FSCÊǸÎÔà·ÇʵÖÊϸ°ûÖ®Ò»£¬²¢·¢ÏÖÖü֬ϸ°ûÓë³ÉÏËάϸ°ûÏàËÆ»òÈÏΪFSCÊǼ¡³ÉÏËάϸ°ûµÄǰÌå.Òò´Ë¶¯Ì¬¹Û²ìѪÇåLN£¬¶ÔÕÆÎÕ±ûÐ͸ÎÑ×ÏËά»¯µÄ³Ì¶ÈºÍ·¢Õ¹Ç÷ÊÆ¾ßÓÐÖØÒªµÄÁÙ´²ÒâÒå.ª¤ª¤
4 ²Î¿¼ÎÄÏ×
1 Fridman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis, 1990;10(1):20-29ª¤
2 ɽÄÚÕæÒ⣬ÖÐÔÕýÐÛ£¬»§Ìï¸ÕÌ«ÀÉ£¬µÈ.¸Î¼²»¼¤Ë¤©¤±¤ðϸ°ûÍâ¥Þ¥È¥ê¥Ä¥¯¥½¥¹³É·Ö²â¶¨¤ÎÁÙ´²µÄÒâÒå.ÄÚ¿Æ£¬1993£»71(2)£º236-239ª¤
3 Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: Role of fat-storing cells in fibrogenesis.
Semin Liver Dis, 1990;10(1):30-46ª¤
4 Íõ½Ü¾ü£¬¿×ÏÜÌΣ¬Àîʯ£¬µÈ.ѪÇå²ãÕ³µ°°×±ä»¯·´Ó³ÂýÐԸβ¡µÄ²¡Àí¸Ä±ä.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬1994;10(3):136-139ª¤
5 ¸ß·å£¬¿×ÏÜÌΣ¬Ð»Ó³»ª£¬µÈ.²ãÕ³µ°°×Óë¸ÎÓ²±äµÄ¶¯ÎïʵÑéÑо¿.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬1995£»11(1)£º34-36ª¤
6 Àî´«µÀ.¸ÎÏËά»¯ÑªÇå±êÖ¾ÎïµÄнøÕ¹.¹úÍâҽѧÁÙ´²ÉúÎﻯѧ¼ìÑé·Ö²á£¬1994£»15(1)£º3-53